REFRACTORY SOLID CANCER PATIENTS UNEXPOSED TO IMMUNOTHERAPY

Clinical trials for REFRACTORY SOLID CANCER PATIENTS UNEXPOSED TO IMMUNOTHERAPY explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY SOLID CANCER PATIENTS UNEXPOSED TO IMMUNOTHERAPY trials appear

Sign up with your email to follow new studies for REFRACTORY SOLID CANCER PATIENTS UNEXPOSED TO IMMUNOTHERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for tough cancers: trial tests personalized immune drug

Disease control Not yet recruiting

This study is testing a personalized immunotherapy drug called tislelizumab for patients with advanced solid cancers that have stopped responding to standard treatments. It will enroll about 72 patients whose tumors show a specific genetic signature suggesting they might respond …

Matched conditions: REFRACTORY SOLID CANCER PATIENTS UNEXPOSED TO IMMUNOTHERAPY

Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control

Last updated Mar 25, 2026 14:09 UTC

REFRACTORY SOLID CANCER PATIENTS UNEXPOSED TO IMMUNOTHERAPY

Get alerted when new REFRACTORY SOLID CANCER PATIENTS UNEXPOSED TO IMMUNOTHERAPY trials appear

New hope for tough cancers: trial tests personalized immune drug